G2G Bio Secures Australian Patent for Extended-Release Semaglutide Formulation

[Financial News] G2G Bio has secured an Australian patent for high-dose extended-release formulation technology using semaglutide, the active ingredient in the obesity treatment Wegovy. Alongside securing rights to formulation technology for developing long-acting obesity treatments, the company plans to accelerate commercialization based on its co-development project with Samsung Bioepis.
G2G Bio said on the 13th that it had obtained an Australian patent for “Extended-Release Microparticle Pharmaceutical Composition Comprising Semaglutide or a Pharmaceutically Acceptable Salt Thereof, and Method for Preparing the Same.”
The patent covers formulation technology that encapsulates semaglutide in extended-release microspheres to ensure its effects last for an extended period. Extended-release formulations are designed to release a drug in the body over a set period and can be used to lengthen the dosing interval.
The related pipeline is a project for which G2G Bio signed a co-development and technology transfer agreement with Samsung Bioepis and Epis Nex Lab in March this year. The company is pursuing the development of long-acting obesity treatments based on the technology.
The company’s partnership with an existing global pharmaceutical company also underwent a change. In January 2023, G2G Bio signed a co-development agreement with a global pharmaceutical company for the active ingredient in question and conducted a technology evaluation. However, after subsequently signing a technology transfer agreement with another company, it decided not to pursue further discussions with its existing partner regarding semaglutide.
However, the collaboration with the existing global pharmaceutical company itself has not ended. G2G Bio said, “We are continuing discussions on technology partnerships involving a number of new active ingredients in addition to semaglutide.”

[email protected] Jung Sang-hee Reporter